An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 Months
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 6
- 主要终点
- Dose limiting toxicities (DLT)
研究概览
简要总结
The objective of REVOCAN study is to assess the abrogation of PARP inhibitors resistance in patients with relapsed platinum sensitive ovarian cancer treated with PARP inhibitors in maintenance since at least 6 months and who have only an increase of CA 125 without any progression according to RECIST criteria. AsiDNATM at 600 mg will be tested in addition to PARP inhibitors given according to the label in REVOCAN study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
- •Female aged ≥ 18 years (no upper limit of age) at the time of consent signature.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy of at least 3 months.
- •Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer regardless BRCA status.
- •Availability of BRCA status;
- •Patient has received at least 2 previous courses of platinum-containing therapy and has a disease that was considered platinum sensitive that means in response (complete or partial) to the last platinum course leading to the administration of Niraparib, or Rucaparib, or Olaparib (PARP inhibitors).
- •The patient has received Niraparib in maintenance for at least 6 months and who has only an increase of CA125 at least twice the upper limit of normal within 2 weeks prior to starting treatment without any progression according to RECIST criteria or according to clinical assessment
- •Patient should be treated within 2 weeks after CT scan without any progression according to RECIST criteria
- •Patient with adequate biological parameters at baseline defined as:
- •absolute neutrophil count (ANC) ≥ 1.5 x 109/L,
- •hemoglobin (Hb) level ≥ 9g/dL,
- •platelet count ≥ 100 x 109/L,
- •total bilirubin level ≤ 1.5 Upper Limit Normal (ULN),
- •aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5x ULN
- •calculated glomerular filtration rate (GFR) ≥ 60 mL/min/1.73m2 (per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula),
- •INR ≤ 1.2 (except if patient treated with anti-vitamine K); anticoagulation with anti-vitamin K and Low Molecular Weight Heparin [LMWH] is allowed.
- •Patient of childbearing potential must agree to use adequate contraception prior to study entry, during the study and for 3 months after the study participation
- •Patient of childbearing potential must have a serum negative pregnancy test within 4 days prior to first administration. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.
- •Patient must be affiliated to a social security system or an equivalent system.
排除标准
- •Patient has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancer
- •Patient treated concomitantly with bevacizumab
- •Patient previously treated with PARPi as first line maintenance
- •Other Malignancy within the last 5 years except curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix, and in situ breast cancer
- •Patient with central nervous system (CNS) metastases;
- •Other tumor location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery or radiation therapy, such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture).
- •Patient with uncontrolled disease-related metabolic disorder (e.g., hypercalcemia, SIADH) or uncontrolled diabetes.
- •Quantitative total urine protein > 1.0 g/24 hour at baseline
- •Patient with uncontrolled congestive heart failure defined as New York Heart Association (NYHA) class III or IV, uncontrolled hypertension, unstable heart disease (e.g., coronary artery disease with unstable angina or myocardial infarction within 6 months before study treatment administration).
- •Patient with significant ECG abnormalities defined as any cardiac dysrhythmia (> grade 2) (i.e., significant ventricular arrhythmia as persistent ventricular tachycardia and/or ventricular fibrillation; severe conduction disorders as atrio-ventricular block 2 and 3, sino-atrial block) or baseline QT/QTc interval >480 milliseconds (ms).
- •Patient with significant chronic liver disease (e.g., significant fibrosis,known cirrhosis) or active HBV or HCV infection; if AgHbs positive, an effective antiviral treatment to prevent hepatitis B reactivation is recommended.
- •Patient with HIV infection or an active infection requiring specific antiinfective therapy are not eligible until all signs of infection have resolved, and this within 2 weeks prior to the first study treatment administration.
- •Patient whose medical, psychological including alcohol or drug abuse, or surgical conditions are unstable and may affect the study completion and/or compliance and/or the ability to give informed consent.
- •Participation in another clinical trial with any investigational drug within 28 days prior to first study drug administration.
- •Vulnerable adult patients benefiting from a specific legal protection status.
- •Patient who has received mouse antibodies (unless the assay used has been shown not to be influenced by HAMA4,5) or if there has been medical and/or surgical interference with their peritoneum or pleura during previous 28 days
- •Patient pregnant or breastfeeding
研究组 & 干预措施
AsiDNA in addition to Niraparib
Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
干预措施: AsiDNA (Drug)
AsiDNA in addition to Niraparib
Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
干预措施: Niraparib (Drug)
AsiDNA in addition to Niraparib
Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
干预措施: Olaparib (Drug)
AsiDNA in addition to Niraparib
Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
干预措施: Rucaparib (Drug)
结局指标
主要结局
Dose limiting toxicities (DLT)
时间窗: 21 days
Occurrence of cases of Dose Limiting Toxicity (DLT) will be recorded and reviewed according to a predefined definition. DLTs include the following specific treatment-related AEs occurring during the first 21 days (from D1 to D21) treatment period (based on the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events (AE) \[CTCAE\] scale, version 5.0 defined as: * Haematological toxicity: 1. Grade 4 neutropenia lasting ≥ 7 days, 2. Febrile Neutropenia, 3. Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding. * Non haematological toxicity: Any drug-related non-hematological toxicity grade ≥ 3 toxicity (except alopecia, fatigue, nausea, controlled hypertension and vomiting adequately treated with antiemetic treatment and non-clinically significant laboratory values abnormalities).
次要结局
未报告次要终点